Fuller & Thaler Asset Management Inc. Purchases 12,910 Shares of Hologic, Inc. $HOLX

Fuller & Thaler Asset Management Inc. boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 57.0% during the 1st quarter, Holdings Channel reports. The fund owned 35,575 shares of the medical equipment provider’s stock after buying an additional 12,910 shares during the period. Fuller & Thaler Asset Management Inc.’s holdings in Hologic were worth $2,197,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new position in Hologic in the first quarter worth approximately $34,000. Allworth Financial LP lifted its holdings in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 216 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Hologic in the first quarter valued at approximately $42,000. Larson Financial Group LLC lifted its holdings in shares of Hologic by 6,016.7% in the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 722 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new position in shares of Hologic in the fourth quarter valued at approximately $49,000. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of HOLX opened at $68.76 on Thursday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $15.29 billion, a price-to-earnings ratio of 28.53, a PEG ratio of 2.46 and a beta of 0.49. The stock has a 50 day moving average of $65.79 and a 200 day moving average of $62.55. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the business posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on HOLX. Mizuho set a $75.00 target price on Hologic in a report on Thursday, July 31st. Stephens dropped their target price on Hologic from $77.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, May 13th. Argus upgraded Hologic from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a report on Monday. Morgan Stanley raised their target price on Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a report on Thursday, July 31st. Finally, Citigroup raised Hologic from a “neutral” rating to a “buy” rating and increased their price target for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.